Review
Microbiology
Rana Abdelqader, Hanan Hasan, Lo'ai Alanagreh
Summary: This systematic review examined the prevalence and circulating genotypes of Human bocavirus (HBoV) in respiratory and stool samples from patients of all age groups in the Middle East and North Africa from 2005 to February 2021. The study included 65 articles and found HBoV to be common in children and adults in the MENA region, highlighting the need for more data on coinfection of HBoV and other viruses such as SARS-CoV-2 in children with acute bronchiolitis.
Article
Oncology
Annika Kasprzak, Kathrin Nachtkamp, Norbert Gattermann, Ulrich Germing
Summary: This article discusses the prognostic scoring systems for myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). It highlights the limitations of current scoring systems and emphasizes the importance of patient and disease-related parameters in assessing prognosis. The article also identifies areas for further investigation.
Article
Biochemistry & Molecular Biology
Xiaoqing Xie, Daria Frank, Pradeep Kumar Patnana, Judith Schuette, Yahya Al-Matary, Longlong Liu, Lanying Wei, Martin Dugas, Julian Varghese, Subbaiah Chary Nimmagadda, Cyrus Khandanpour
Summary: The study identified a therapeutic role for curcumin treatment in delaying the expansion of GFI1-36N or -KD, NUP98-HODXD13 leukemic cells and prolonging AML-free survival.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Hematology
Irina Amitai, Michelle Geddes, Nancy Zhu, Mary-Margaret Keating, Mitchell Sabloff, Grace Christou, Brian Leber, Dina Khalaf, Heather A. Leitch, Eve St-Hilaire, Nicholas Finn, April Shamy, Karen Yee, John Storring, Thomas Nevill, Robert Delage, Mohamed Elemary, Versha Banerji, Lisa Chodirker, Lee Mozessohn, Anne Parmentier, Mohammed Siddiqui, Alexandre Mamedov, Liying Zhang, Rena Buckstein
Summary: Incorporating patient-reported fatigue with traditional risk classification enhances survival prediction in higher-risk MDS patients, leading to distinct subgroups with different survival outcomes. This highlights the importance of considering patient-reported outcomes in refining overall survival predictions for higher-risk MDS.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Review
Oncology
Jan Philipp Bewersdorf, Amer M. Zeidan
Summary: MDS and CMML are two distinct blood cancers with variable symptoms and risks. Management decisions should be individualized and based on validated risk stratification tools. Supportive care is the mainstay for lower-risk patients, while bone marrow transplant is the only curative option for higher-risk patients.
Article
Medicine, General & Internal
Huan Li, Fang Hu, Robert Peter Gale, Mikkael A. Sekeres, Yang Liang
Summary: Myelodysplastic syndromes (MDS) are a group of blood cancers characterized by dysregulated hematopoiesis and risk of transformation to acute myeloid leukemia. Prognostic systems can predict survival in MDS patients. Treatment goals differ for low-risk and high-risk MDS, with the aim to improve quality of life and prolong survival, respectively. Hematopoietic cell transplantation can cure MDS, but it is not widely used.
NATURE REVIEWS DISEASE PRIMERS
(2022)
Article
Oncology
Michael Mann, Andrew M. Brunner
Summary: This review discusses the approaches to immunologic therapies in myelodysplastic syndromes (MDS), which can be broadly categorized into therapies that target immune effector cells and enhance antileukemic effect, and therapies that target immunological markers on MDS progenitors themselves. The review provides insights into the rationale, clinical results, and future directions of these therapies.
CURRENT PROBLEMS IN CANCER
(2022)
Article
Hematology
Krzysztof Madry, Karol Lis, Pierre Fenaux, David Bowen, Argiris Symeonidis, Moshe Mittelman, Reinhard Stauder, Jaroslav Cermak, Guillermo Sanz, Eva Hellstrom-Lindberg, Saskia Langemeijer, Luca Malcovati, Ulrich Germing, Mette Skov Holm, Agnes Guerci-Bresler, Dominic Culligan, Laurence Sanhes, Ioannis Kotsianidis, Corine van Marrewijk, Simon Crouch, Theo de Witte, Alex Smith
Summary: Information on causes of death and the impact of myelodysplastic syndromes (MDS) on survival in patients with lower-risk MDS is limited. This study shows that MDS and its related complications play a crucial role in the outcome of patients with lower-risk MDS.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Seongseok Yun, Susan M. Geyer, Rami S. Komrokji, Najla H. Al Ali, Jinming Song, Mohammad Hussaini, Kendra L. Sweet, Jeffrey E. Lancet, Alan F. List, Eric Padron, David A. Sallman
Summary: The clinical relevance of serial molecular annotation during treatment in patients with myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (sAML) was investigated. The study found that mutation clearance (NGS-) was associated with improved overall survival (OS) and represented a potential biomarker for treatment outcomes, highlighting the importance of serial NGS evaluations during treatment.
Review
Biochemistry & Molecular Biology
Ekaterina Balaian, Manja Wobus, Martin Bornhaeuser, Triantafyllos Chavakis, Katja Sockel
Summary: MDS is a clonal stem cell disorder characterized by genetic alterations, inflammatory processes, and changes in cellular metabolism. These abnormalities lead to dysfunction of HSPCs and niche cells, promoting clone expansion and increasing the risk for AML.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Oriol Calvete, Julia Mestre, Andres Jerez, Francesc Sole
Summary: The classification of secondary myelodysplastic neoplasms (MDSs) in patients with a previous primary tumor is still controversial due to the lack of an established consensus risk factor-based classification. Current classifications consider separate etiologies based on exposure to cytotoxic therapy and genetic predisposition, despite the evidence of overlapping risk factors. This review aims to summarize the current knowledge of secondary MDS etiologies and suggests the need for future classifications that take into account all risk factors and their interactions.
Review
Oncology
Caner Saygin, Lucy A. Godley
Summary: Myelodysplastic syndrome (MDS) is a bone marrow disease characterized by the inability to produce normal numbers of blood cells. Different types of MDS are driven by distinct biological pathways, with advancements in treatment strategies based on molecular understanding. The recognition of precursor conditions may allow for strategies to delay or prevent MDS development.
Review
Oncology
Yan Jiang, Su-Jun Gao, Benoit Soubise, Nathalie Douet-Guilbert, Zi-Ling Liu, Marie-Berengere Troadec
Summary: Gene variants, particularly TP53 mutations, play a crucial role in the prognosis of myelodysplastic syndromes (MDS), being associated with higher risk categories, resistance to traditional therapies, rapid leukemic transformation, and poor outcomes. Current prognosis classification systems for MDS do not consider gene variants, but the impact is significant on the clinical heterogeneity and prognosis of the disease.
Article
Hematology
Mrinal M. Patnaik, Ayalew Tefferi
Summary: Ring sideroblasts (RS) are erythroid precursors with abnormal perinuclear mitochondrial iron accumulation, associated with myeloid neoplasms MDS-RS and MDS/MPN-RS-T; SF3B1 mutations are common in these diseases; treatment options include luspatercept for anemia and consideration of aspirin therapy in MDS/MPN-RS-T.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Article
Oncology
Andrew M. Brunner, Alexander Gavralidis, Najla Al Ali, Anthony Hunter, Rami Komrokji, Amer Zeidan, David A. Sallman
Summary: This study evaluated the treatment response and survival rate of MDS patients treated with DNMTI therapy. The results showed that patients who achieved a CRh response had similar survival and duration on therapy as patients who achieved a CR response, and superior to other responses. These data support further evaluation of the importance of CRh as a response criteria and in clinical trials.
BLOOD CANCER JOURNAL
(2022)
Article
Pathology
Umberto Malapelle, Pasquale Pisapia, Antonino Iaccarino, Massimo Barberis, Claudio Bellevicine, Hans Brunnstrom, Dario de Biase, Giovanna De Maglio, Kajsa Ericson Lindquist, Matteo Fassan, Gabriella Fontanini, Elisa Gruppioni, Paul Hofman, Sabine Merkelbach-Bruse, Miguel A. Molina Vila, Anais Pujals, Ida Rapa, Luisella Righi, Rafael Rosell, Oliver Schildgen, Verena Schildgen, Fernando C. Schmitt, Giovanni Tallini, Sara Vander Borght, Elena Vigliar, Marco Volante, Svenja Wagener-Ryczek, Birgit Weynand, Giancarlo Troncone
Summary: The workload of molecular testing for patients with advanced-stage lung cancer during the lockdown showed little variations. Local strategies to overcome health emergency-related issues included the preference for RT-PCR tissue-based testing methodologies and, occasionally, for liquid biopsy.
JOURNAL OF CLINICAL PATHOLOGY
(2021)
Article
Ophthalmology
R. Michael Dutescu, Peter Banasik, Oliver Schildgen, Norbert Schrage, Daniel Uthoff
Summary: This study found a higher percentage of coronavirus RNA in tears of SARS-CoV-2 positive patients using tear fluid sampling technique similar to oropharyngeal lavage compared to earlier reports using conjunctival swabs. Although patients in intensive care showed ocular symptoms, viral conjunctivitis was not observed in any patients.
Letter
Public, Environmental & Occupational Health
Jessica Luesebrink, Verena Schildgen, Oliver Schildgen
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
(2021)
Article
Medicine, General & Internal
Vanessa Vedder, Verena Schildgen, Jessica Lusebrink, Ramona Liza Tillmann, Birgitta Domscheit, Wolfram Windisch, Christian Karagiannidis, Michael Brockmann, Oliver Schildgen
Summary: The study compared the cytological profiles of BALs from patients infected with various respiratory pathogens, finding that different pathogens caused distinct cell pattern changes but no general cell distribution pattern. Although the cytology pattern of BAL fluid is not specific enough to be used as the sole diagnostic criterion for COVID-19, it may support clinical decision-making.
Article
Microbiology
Verena Schildgen, Sabrina Demuth, Jessica Luesebrink, Oliver Schildgen
Summary: This study analyzed the performance of three different rapid antigen tests in a clinical setting, showing varying specificities and sensitivities which did not entirely meet all expectations. Therefore, careful evaluation is needed when considering their benefits for specific testing strategies and settings.
Correction
Oncology
Verena Schildgen, Monika Pieper, Soumaya Khalfaoui, Wolfgang H. Arnold, Oliver Schildgen
Letter
Anesthesiology
Ulrich Limper, Jerome Defosse, Oliver Schildgen, Frank Wappler
BRITISH JOURNAL OF ANAESTHESIA
(2021)
Article
Pathology
Tiffany Haiduk, Michael Brockmann, Ramona-Liza Tillmann, Monika Pieper, Jessica Lusebrink, Verena Schildgen, Oliver Schildgen
Summary: Lung and colorectal cancers have high mortality rates and were not affected by the COVID19 pandemic in terms of personalized diagnostics and therapy. Due to disruption of delivery chains, alternative testing methods, such as the Biocartis IdyllaTM platform, were implemented, showing acceptable sensitivity and specificity for therapy decision making.
EXPERIMENTAL AND MOLECULAR PATHOLOGY
(2021)
Editorial Material
Pathology
Oliver Schildgen
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
(2021)
Letter
Infectious Diseases
Andreas Kretschmer, Annelene Kossow, Barbara Gruene, Oliver Schildgen, Tim Mathes, Verena Schildgen
JOURNAL OF INFECTION
(2022)
Expression of Concern
Virology
Eric O. Freed, Oliver Schildgen
Letter
Infectious Diseases
Verena Schildgen, Jessica Luesebrink, Oliver Schildgen
JOURNAL OF INFECTION
(2022)
Letter
Infectious Diseases
Verena Schildgen, Jessica Luesebrink, Oliver Schildgen
JOURNAL OF INFECTION
(2023)
Letter
Infectious Diseases
M. Nitsch, T. Stahlhut, O. Schildgen, V. Schildgen
NEW MICROBES AND NEW INFECTIONS
(2022)
Letter
Infectious Diseases
Verena Schildgen, Jessica Luesebrink, Oliver Schildgen
NEW MICROBES AND NEW INFECTIONS
(2022)
